GIA632 for Vitiligo
(VITESS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive GIA632 or placebo during the 48-week core period to assess dose-response relationship and treatment effect
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Assessment of longer-term safety and efficacy in an extension period
What Are the Treatments Tested in This Trial?
Interventions
- GIA632
How Is the Trial Designed?
5
Treatment groups
Experimental Treatment
Placebo Group
GIA632 will be administered during the 48-week core period.
GIA632 will be administered during the 48-week core period.
GIA632 will be administered during the 48-week core period.
GIA632 will be administered during the 48-week core period.
Placebo will be administered during the 48-week core period.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.